Compare HIMX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | BEAM |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2006 | 2019 |
| Metric | HIMX | BEAM |
|---|---|---|
| Price | $13.75 | $27.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $50.75 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $7.79 | $33.77 |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $6.85 | $15.60 |
| 52 Week High | $25.09 | $38.26 |
| Indicator | HIMX | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 44.83 |
| Support Level | $12.49 | $26.23 |
| Resistance Level | $16.07 | $29.21 |
| Average True Range (ATR) | 0.72 | 1.46 |
| MACD | 0.26 | 0.18 |
| Stochastic Oscillator | 80.34 | 67.89 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.